drugset / Trial / NCT05552495

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

NCT05552495

Phase 1 Completed 31 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-386 in healthy volunteers under fasting conditions.

Timeline

Start
2022-09-23
Primary completion
2022-11-27
Completion
2022-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-386 Unknown
Subject D013 Unknown
Subject D326 Unknown
Subject D337 Unknown